Palvella Therapeutics (FRA:PI6) Float Percentage Of Total Shares Outstanding: 88.37% (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PI6 Palvella Therapeutics Inc FRA:PI6
20 GF Score
Price €125.00
! 2 Warning Signs
View Full Analysis

What is Palvella Therapeutics Float Percentage Of Total Shares Outstanding?

Palvella Therapeutics FRA:PI6 +1.63% 20 Float Percentage Of Total Shares Outstanding is 88.37% as of Jul. 25, 2026. GuruFocus rates FRA:PI6 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Palvella Therapeutics's float shares is 12.67 Mil. Palvella Therapeutics's total shares outstanding is 14.34 Mil. Palvella Therapeutics's float percentage of total shares outstanding is 88.37%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Palvella Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Palvella Therapeutics's Institutional Ownership is 48.99%.

FRA:PI6
20GF Score
Palvella Therapeutics Inc FRA:PI6
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Palvella Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Palvella Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=12.67/14.34
=88.37%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 88.37% mean?
Palvella Therapeutics (FRA:PI6) has a Float Percentage Of Total Shares Outstanding of 88.37% as of Jul. 25, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Palvella Therapeutics and its competitors.
Is Palvella Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Palvella Therapeutics' current Float Percentage Of Total Shares Outstanding is 88.37%. Overall, Palvella Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Palvella Therapeutics' Float Percentage Of Total Shares Outstanding compare to GENB and NKTR?
Palvella Therapeutics' Float Percentage Of Total Shares Outstanding of 88.37% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Palvella Therapeutics and its competitors. Palvella Therapeutics's current Float Percentage Of Total Shares Outstanding is 88.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palvella Therapeutics stock overvalued right now?
Palvella Therapeutics (FRA:PI6) has a current Float Percentage Of Total Shares Outstanding of 88.37%. The current Float Percentage Of Total Shares Outstanding is 88.37%. Palvella Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Palvella Therapeutics (FRA:PI6), the current Float Percentage Of Total Shares Outstanding is 88.37% as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Palvella Therapeutics Business Description

Other Exchanges PVLA:USA
Address 353 W. Lancaster Avenue, Suite 200, Wayne, PA, USA, 19087
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
20GF Score

Get the complete analysis for FRA:PI6

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€125.00
Price